Explore the words cloud of the ENTRANCE project. It provides you a very rough idea of what is the project "ENTRANCE" about.
The following table provides information about the project.
NTRANS TECHNOLOGIES BV
|Coordinator Country||Netherlands [NL]|
|Total cost||1˙514˙200 €|
|EC max contribution||1˙514˙200 € (100%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2017-09-01 to 2019-10-31|
Take a look of project's partnership.
|1||NTRANS TECHNOLOGIES BV||NL (UTRECHT)||coordinator||1˙514˙200.00|
NTrans Technologies BV has developed iTOP; a novel and extremely effective method to deliver highly relevant bioactive molecules (including DNA, RNA, active proteins, and their combinations) into mammalian cells. This includes the efficient delivery of such molecules inside the most biologically and biomedically relevant cell types (e.g. human primary and stem cells), which are notoriously difficult to manipulate. iTOP technology has been scientifically validated (published in the top scientific journal Cell in 2015) and patented (WO2015028969).
iTOP addresses the unmet need of researchers and drug developers to be able to transfect a range of biomolecules into biologically relevant cell models; in particular to study genetic diseases and to underpin results obtained with standard immortalized cell lines.
The ENTRANCE project includes the necessary steps towards market entry of the iTOP research-use-only (RUO) kit: The development of (i) an iTOP RUO kit and (ii) an iTOP on-line community as innovative marketing tool that will support proper use and stimulate efficient application of the technology. The ENTRANCE project will thus provide the scientific community access to the novel iTOP tool, facilitate direct access of iTOP kit users to the NTrans support team, and enable sharing of user experiences via an iTOP interactive forum.
ENTRANCE will instigate a revolution in biomedical sciences by empowering both researchers and drug developers to manipulate the most relevant cell types with unprecedented efficiency. This will allow the field to move forward at a significantly accelerated pace.
The iTOP RUO kit will generously earn back the investments within 4 years, and help to create a buzz around the merits and possibilities of the technology. The latter is of immense value to the SME forecasted to support 16 FTE by 2020, with the ambition to expand its product pipeline and become leader in technologies for delivery of therapeutic biomolecules into primary cells.
|3.4b iTOP community platform completed||Websites, patent fillings, videos etc.||2020-03-24 11:33:03|
|1.5b First lot of sample kit produced||Demonstrators, pilots, prototypes||2020-02-27 15:22:05|
|1.3 Digital user manuals completed||Documents, reports||2020-02-27 15:21:52|
|3.5b Final version of the DMP||Documents, reports||2019-07-30 13:59:42|
|3.1b Report of the Mid-Term event||Documents, reports||2019-05-31 11:55:55|
|3.3a Dedicated web pages for ENTRANCE||Websites, patent fillings, videos etc.||2019-05-31 11:55:51|
|3.1a Report of the Kick-off Event||Documents, reports||2019-05-31 11:55:52|
|3.5a First version of DMP||Documents, reports||2019-05-31 11:56:04|
Take a look to the deliverables list in detail: detailed list of ENTRANCE deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ENTRANCE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ENTRANCE" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
Global Alliance for Chronic Diseases SecretariatRead More
Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired PneumoniaRead More